Our CEO Ulrik Mouritzen spoke with Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study
21 August 2025
An Oral Approach for Diabetic Retinopathy
05 August 2025
The Medicine Maker
View Story
Phase Ib trial complete in patients with diabetic retinopathy
27 June 2025
Drug Discovery World (DDW)
View Story
An oral treatment for diabetic retinopathy
26 June 2025
Association of Optometrists (AOP)
View Story
Biotekselskab får positive resultater med lægemiddelhåb mod øjensygdomme
25 June 2025
MedWatch.dk
View Story [Behind paywall – Danish Language]
Breye Therapeutics has First patient dosed in phase 1b/2a trial of oral danegaptide for diabetic retinopathy
26 Jan 2024
Healio
View Story
Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
25 January 2024
PharmiWeb
View Story
The oral therapeutic that could change our approach to retinal disease
13 Oct 2023
Ophthalmology Times Europe
View Story
Golgi and Breye partner to develop P2X7 receptor antagonist programme
25 July 2023
Pharmaceutical Technology
View Story
Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer
25 July 2023
BioWorld
View Story [Behind Paywall]
Five ophthalmology biotech companies to look out for
1 June 2023
Labiotech
View Story
Breye Therapeutics Strengthens Management Team and Board
20 April 2023
FirstWord Pharma
View Story
Oral alternative to eye injections? Novo backs startup’s big plan to repurpose shelved drug
10 Nov 2022
Endpoints
View Story [Behind Paywall]
Breye launched to develop oral therapy for diabetic retinopathy
10 Nov 2022
BioWorld
View Story [Behind Paywall]
